Experimental cell therapy targets aggressive lymphoma that returns after treatment
NCT ID NCT06912529
Summary
This study aimed to test a personalized cell therapy called axicabtagene ciloleucel for adults with a specific type of lymphoma that has come back or did not respond to initial treatment. The goal was to see if this therapy could control the disease and how safe it was. The trial was terminated early after enrolling only one participant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie Universitätsklinikum Münster
Münster, 48149, Germany
Conditions
Explore the condition pages connected to this study.